Skip to main content
Cidara Therapeutics, Inc. logo

Cidara Therapeutics, Inc. — Investor Relations & Filings

Ticker · CDTX ISIN · US1717572069 LEI · 549300IHQ9Z7RI1X2D22 US Manufacturing
Open in API
Filings indexed 793 across all filing types
Latest filing 2018-06-15 Director's Dealing
Country US United States of America
Listing US CDTX

About Cidara Therapeutics, Inc.

https://www.cidara.com/

Cidara Therapeutics, Inc. is a biotechnology company that develops targeted immunotherapies and novel anti-infectives for patients with serious diseases. The company utilizes its proprietary Cloudbreak® platform to create drug-Fc conjugates (DFCs). These DFCs are engineered as 'single molecule cocktails' by coupling targeted small molecules or peptides to a human antibody fragment (Fc). This approach is designed to directly inhibit disease targets, such as fungal or viral pathogens, while simultaneously engaging the patient's immune system. The company's focus is on developing therapies for the treatment and prevention of life-threatening infections and other serious conditions.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2018-06-15 English
FORM 4 SUBMISSION
Director's Dealing
2018-06-15 English
FORM S-3MEF
Capital/Financing Update Classification · 100% confidence The document is a Form S-3 Registration Statement filed with the SEC, which is a registration statement for securities offerings under the Securities Act of 1933. It includes details about the securities to be registered, the registrant's information, and exhibits such as legal opinions and consents. This type of filing is related to capital raising activities and financing. It is not an annual report, earnings release, or any other financial report but specifically a registration statement for securities issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is sufficient and contains substantive content, not just an announcement or certification, so it is not RPA or RNS.
2018-06-05 English
WITHDRAWAL REQUEST
Regulatory Filings Classification · 100% confidence The document is a letter from Cidara Therapeutics, Inc. to the SEC requesting withdrawal of a Registration Statement on Form S-3. It references regulatory rules under the Securities Act and discusses procedural matters related to the withdrawal and fee credits. There is no financial data, report content, or presentation of results. The document is a regulatory filing related to compliance and procedural request rather than a financial report or announcement of financial results. It fits best under Regulatory Filings (RNS) as a miscellaneous regulatory communication that does not fit other categories.
2018-06-05 English
THE SCHEDULE 13G
Major Shareholding Notification
2018-06-04 English
Major Shareholding Notification 2018
Major Shareholding Notification
2018-06-04 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.